Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.52 |
| ▸ | GLRB | P48167 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18680588 | 0.87 | GLRA3 (0.59) | GLRA3GLRBCA12CA1CA2 | |
| SCHEMBL2065024 | 0.87 | GLRA3 (0.59) | GLRA3GLRBCA12CA1CA2 | |
| SCHEMBL16960854 | 0.83 | CA12 (0.44) | GLRA3GLRBCA12CA1CA2 | |
| SCHEMBL3171046 | 0.83 | — | — | |
| SCHEMBL521670 | 0.81 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1401499 | 0.81 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20633340 | 0.81 | GLRA3 (0.54) | GLRA3GLRBCA12CA1CA2 | |
| SCHEMBL21248382 | 0.79 | NOTUM (0.53) | GLRA3GLRBCA12CA1CA2 | |
| SCHEMBL15485016 | 0.79 | GLRA3 (0.52) | GLRA3GLRBCA12CA1CA2 | |
| SCHEMBL20610058 | 0.79 | NOTUM (0.60) | GLRA3GLRBCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869350-B | Alkynyl compounds, their preparation and their therapeutic use | 赛诺菲 | 2023-05-02 | — | — | CN | disclosed |
| US-11078160-B2 | Ethynyl compounds, their preparation and their therapeutic use for the treatment of malaria | SANOFI (FR) | 2021-08-03 | — | — | US | disclosed |
| US-11078160-B2 | Ethynyl compounds, their preparation and their therapeutic use for the treatment of malaria | SANOFI (FR) | 2021-08-03 | — | — | US | disclosed |
| US-20200281909-A1 | ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE FOR THE TREATMENT OF MALARIA | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-09-10 | — | — | US | disclosed |
| US-20200281909-A1 | ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE FOR THE TREATMENT OF MALARIA | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-09-10 | — | — | US | disclosed |
| EP-3649109-A1 | ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE FOR THE TREATMENT OF MALARIA | Sanofi (FR) | 2020-05-13 | — | — | EP | disclosed |
| CN-110869350-A | Alkynyl compounds, their preparation and their therapeutic use | 赛诺菲 | 2020-03-06 | — | — | CN | disclosed |
| WO-2019008027-A1 | ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE FOR THE TREATMENT OF MALARIA | SANOFI (FR) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008027-A1 | ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE FOR THE TREATMENT OF MALARIA | SANOFI (FR) | 2019-01-10 | — | — | WO | disclosed |
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078160-B2 | Ethynyl compounds, their preparation and their therapeutic use for the treatment of malaria | CYP11B2, CYP11B1, RHOT2 | GLRA3 2211/4885GLRB 3268/4885CA12 2841/4885 |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | GLRA3 2081/4885GLRB 3692/4885CA12 3385/4885 |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | GLRA3 2081/4885GLRB 3692/4885CA12 3385/4885 |
| US-20200281909-A1 | ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE FOR THE TREATMENT OF MALARIA | CYP11B2, CYP11B1, RHOT2 | GLRA3 2211/4885GLRB 3268/4885CA12 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.